The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...
The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...
Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower ...
The 15 drugs selected for negotiation include Eli Lilly’s breast-cancer drug Verzenio.
The Centers for Medicare & Medicaid Services just announced the next 15 brand-name medicines selected for Medicare’s drug price negotiation program, which mandates price reductions of at least 25%.
Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into effect until 2028.
The Trump administration on Tuesday announced the next round of prescription drugs up for Medicare price negotiations.
The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...
CMS names medications 2028 for Medicare price negotiation, including Trulicity and Biktarvy, targeting high-cost drugs in ...
President Donald Trump and the Centers for Medicare & Medicaid Services (CMS) recently announced the 15 drugs whose prices ...
The Centers for Medicare and Medicaid Services said Tuesday it seeks to lower Medicare costs for 16 medications by negotiating with their manufacturers. Among them is Biktarvy, a drug taken after HIV ...
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results